Clinical Trial Update: Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)

View source ↗

Summary

Esketamine nasal spray has been approved for marketing for treatment-resistant depression. This update confirms the regulatory approval status and reflects broa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Treatment-resistant Depression

Drugs mentioned

• Spravato (esketamine nasal spray) (Esketamine)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Depressive Disorder, Treatment-Resistant | Status: APPROVED_FOR_MARKETING